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Decades of cancer and leukaemia research have pro-
vided priceless insight into the molecular mechanisms
underlying the development and maintenance of malig-
nancies. The ultimate goal of these findings was, and still
is, discovering discriminating factors enabling detection
or treatment of tumour cells. An important achievement
in this field has been the integration of protein chem-
istry, fluorescence detectors, nanoparticles, optical de-
vices and computational devolvement integrated in the
field of flow cytometry, fluorescence activated cell sort-
ing FACS, data analysis and visualisation. Especially im-
portant is the onset of computational data mining tools
like T-distributed Stochastic Neighbor Embedding (t-
SNE), developed by van der Maatenand Hinton[1] and
further continuous progress of the machine learning al-
gorithms for visualization of the huge amount of data
produced from single cell FACS or mass cytometry anal-
ysis.
This concept has forever changed the way scien-
tists and clinicians approach the search for new thera-
pies, shifting the focus from blanket treatments, such as
chemotherapy, to specific targeted therapies which hold
the stage today. These therapies have shown a profound
impact on the treatment of a variety of human cancers,
but none more so than hematopoietic malignancies. Here
we summarise the targeted therapies currently being used
for the treatment of leukaemias and lymphomas, with a
brief overview of those presently being investigated.
Generally, targeted therapies can be divided into two
main types: small molecule medicines and monoclonal
antibodies. Monoclonal antibodies bind to a specific
antigen abundantly expressed on a malignant cell, and
induce cell death through either apoptosis, complement-
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dependent cytotoxicity or antibody-dependent cellular
cytotoxicity. Additionally, the antibody can be linked
to a toxic molecule (radioisotope or drug) or to the in-
tracellular part of a T cell receptor (Chimeric Antigen
Receptor T-cell, CAR-T) (CAR-T is not covered by this
short presentation, for detailed review see Miliotou and
Papadopoulou, 2018)[2] and thus serve as a highly spe-
cific drug delivery system.
Naked monoclonal antibodies for the CD20 molecule
have been in use for more than 20 years in the treat-
ment of non-Hodgkin lymphoma (NHL) and chronic
lymphocytic leukaemia (CLL), with Rituximab was the
first monoclonal antibody approved for treatment of hu-
man malignancies[3]. Ofatumumab emerged a decade
later as a more stable antibody with a slower dissoci-
ation rate, and has since been approved for the treat-
ment of CLL[4]. It remains the only fully human anti-
CD20 antibody available for treatment. Also Obinu-
tuzumab has been approved for treatment of patients
with previously untreated CLL and refractory follicular
lymphoma[5]. Anti-CD20 antibody has been utilized for
precision radiotherapy, as is the case with Ibritumomab
tiuxetan which bears a radioactive isotope (yttrium-90
or indium-111) and is used for the treatment of NHL[6].
Similarly, Inotuzumab ozogamicin is a conjugate con-
sisting of an anti-CD22 antibody linked to a cytotoxic
agent ozogamicin and it is used primarily for the treat-
ment of acute lymphoblastic leukaemia (ALL)[7]. An-
tibodies for CD33 (Gemtuzumab ozogamicin, for acute
myeloid leukaemia (AML)), CD52 (Alemtuzumab, for
CLL) and CD30 (Brentuximab vedotin, an antibody-
drug conjugate for the treatment of NHL and HL) are
also currently approved for use, and many more, such as
anti-CD27, anti-CD70 and anti-CD25, are still in vari-
ous phases of clinical trials[4–10]. A promising novel ap-
proach to therapeutical monoclonal antibodies is the de-
velopment of bispecific antibodies which target two anti-
gens simultaneously. Blinatumomab binds CD19 on tu-
mour cells and CD3 on T cells which brings them into
close proximity and induces T cells cytotoxicity[11]. Bli-
natumomab is in current use for subsets of ALL, but
there are early results indicating its effectiveness in CLL
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and NHL[12–14]. The effectiveness of these therapies de-
pends highly on the treatment regime, dosage and the
disease in question. In most cases, monoclonal antibod-
ies are not used as a stand-alone therapy but in various
combinations with conventional therapies.
Small molecule medicines in the treatment of
hematopoietic malignancies include tyrosine kinase in-
hibitors, histone deacetylase inhibitors, hypermethyla-
tion inhibitors, and proteasome inhibitors. The main tar-
gets for tyrosine kinase inhibitors (TKI) are PI3K/AKT,
MAPK/ERK, JAK-STAT, STAT5, FLT3 and BTK which
have been reported to be aberrantly activated in various
acute and chronic leukaemias and lymphomas, typically
initiating and maintaining cell proliferation[15, 16]. The
well-known representative of TKIs is the BCR-ABL fu-
sion protein inhibitor used in the treatment of chronic
myelogenous leukaemia (CML). Since this initial dis-
covery, a number of inhibitors have been approved for
use in the treatment of CML, AML and ALL and more
are still in clinical and preclinical trials[17–19].
Histone deacetylases regulate gene expression and,
with it, cell proliferation, differentiation and apopto-
sis. They behave as oncogenes in multiple cancer
types, making them ideal therapeutical targets. Histone
deacetylase inhibitors (HDI) cause cell death by cell cy-
cle arrest, apoptosis induction or autophagy inhibition
but much is unknown of the precise mechanism of ac-
tion. There are currently four approved pan-HDIs for
the treatment of multiple myeloma (Panobinostat) and T-
cell lymphoma (Belinostat, Vorinostat and Romidepsin)
and several more are in phase II and III of clinical tri-
als[20]. All in all, HDIs represent a promising new ther-
apeutic approach, especially when combined with other
anti-cancer agents.
Besides histone modifications, transcription is epige-
netically regulated by DNA methylation. Aberrant DNA
methylation is a common feature of malignancies. In
blood cancers, mutations in DNA methylation regulators,
such as DNMT3A, TET1/2 and IDH1/2, are commonly
found in AML and myelodysplastic syndrome (MDS) in
which the hypermethylation patterns can serve to charac-
terise specific subtypes of the disease[21]. Therefore, hy-
permethymation inhibitors represent an interesting ther-
apeutical target. Azacitidin and Decitabine are approved
for the treatment of AML and MDS. Patients treated with
the inhibitors show an improved overall survival with
limited side effects[22, 23].
Degradation of cellular proteins is a complex process
in which the ubiquitin proteasome pathway represents a
central mechanism. Protein degradation is involved in a
variety of processes and defects in the ubiquitin protea-
some pathway lead to a number of diseases. Inhibiting
protein degradation in cells leads to an accumulation of
damaged or redundant proteins and, thus, to inhibition of
proliferation and induction of apoptosis. Bortesomib was
the first proteasome inhibitor to be approved for use in
multiple myeloma and mantle cell lymphoma, followed
later by carfilzomib and ixazomib, and there is strong
evidence indicating that these drugs could also be effec-
tive in treatment of AML and ALL[24–26]. Even though
a number of inhibitors are currently in clinical trials, the
three aforementioned are the only presently in use.
With the advancement of available knowledge and
technologies, the treatments for hematopoietic malig-
nancies are moving from conventional towards precision
therapies. The novel strategies are, mostly, still used with
chemotherapy or radiotherapy, but their usefulness is ev-
ident in the increase of treatment outcome and patient
survival. Targeted therapies are generally well tolerated
but have a large range of toxicities, mostly impacting the
skin and liver, due to the physiological functions modu-
lated by the drugs. More and more therapeutics are being
invented and tested daily, new uses for known drugs are
being discovered, and it is clear that the future of cancer
treatment lies in targeted therapy.
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